Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

UK Cost Body Finally Approves Limited Use of GSK's Lupus Drug

May 11, 2016 8:37 am | by Ben Hirschler, Reuters | News | Comments

The National Institute for Health and Care Excellence (NICE) said on Tuesday that the drug would be made available under a managed access scheme.


FDA to Re-Evaluate Definition of 'Healthy'

May 11, 2016 8:31 am | by The Associated Press | News | Comments

The Food and Drug Administration will re-evaluate its definition of "healthy," which could eventually change how a range of foods are marketed.

New Research Connects Genetic Variations to Schizophrenia

May 11, 2016 8:29 am | by Rachel Jonas, UCLA, The Conversation | Articles | Comments

To find out, researchers are trying to fill in the blanks between the genetic blueprint (genotype) and psychiatric disorder (psychiatric phenotype)


Eli Lilly's Plaque Psoriasis Drug Could Achieve Future Blockbuster Status

May 11, 2016 8:28 am | by Alexandra Annis, MSc, Immunology Analyst, GlobalData | Articles | Comments

The recommended dosing for Taltz is an initial 160 milligrams (mg) subcutaneous (SC) injection.


Clue for Development of Diagnosis, Treatment of Alzheimer's

May 11, 2016 8:26 am | by Osaka University | News | Comments

This group also found that this phenomenon became prominent at the frequency of about 30 kHz.


Scientists Design Potent Therapeutic "Warheads" That Target Cancer Cells

May 11, 2016 7:30 am | by TSRI | News | Comments

A number of these molecules are already “hidden” in drugs approved by the U.S. Food and Drug Administration (FDA).


Potential Target in Treatment of Oral Cancer Discovered

May 10, 2016 3:00 pm | by Boston University Medical Center | News | Comments

The findings represent a new strategy for marker discovery combining bioinformatics analysis of gathered gene expression datasets. 


EC Approves Additional Indication for Eisai's Anticancer Agent

May 10, 2016 2:00 pm | News | Comments

Halaven is a halichondrin class microtubule dynamics inhibitor with a distinct binding profile.


New Approach to Genetic Analysis Yields Markers to Complex Diseases

May 10, 2016 1:00 pm | by Anne Trafton, MIT News Office | News | Comments

Many diseases, such as cancer, diabetes, and schizophrenia, tend to be passed down through families.


Takeda Receives Gates Foundation Grant for Polio Vaccine

May 10, 2016 10:30 am | by Ryan Bushey, Digital Editor | Articles | Comments

The Bill & Melinda Gates Foundation has awarded Takeda Pharmaceuticals a $38 million grant to support development of a low-cost polio vaccine.


Allergan Plans to Buy Back $10B in Shares, Posts 1Q Profit

May 10, 2016 10:23 am | by The Associated Press | News | Comments

Allergan shares rose 2 percent in premarket trading.


Better Way to Diagnose, Manage Neuroendocrine Tumors

May 10, 2016 8:56 am | by Society of Nuclear Medicine | News | Comments

These findings could have an impact on the future of nuclear medicine.


Treating Hep C: Pay Now or Pay More Later

May 10, 2016 8:55 am | by University of Southern California | News | Comments

The economic studies were funded by the Illinois-based pharmaceutical company AbbVie.


Valeant Pharma Promises to do Better with Deadlines

May 10, 2016 8:53 am | by The Associated Press | News | Comments

Shares of Valeant Pharmaceuticals are sharply higher after the embattled drug company promised to do better with financial filing deadlines.


First U.S. Lab Network to Offer Epigenomics’ Epi proColon

May 10, 2016 8:53 am | News | Comments

Epigenomics AG, the German-American cancer molecular diagnostics company, announced that Laboratory Corporation of America Holdings (LabCorp) is the first laboratory network in the U.S. to offer Epi proColon, a blood-based test for colorectal cancer screening.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.